Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing risk and interest-cost pressure, giving management flexibility to fund operations or strategic initiatives from equity or cash. Over a 2–6 month horizon this lowers bankruptcy risk and preserves optionality for partnerships or M&A.

Stable Equity CushionA stable equity base provides a durable buffer against operating losses, allowing the company to absorb near-term cash burn without immediate refinancing. This supports continuity of R&D and commercialization efforts and reduces likelihood of urgent dilutive financing within months.

Proprietary Product NicheOwning specialized heparin-based coating technology and a focused blood-compatibility product set creates a structural competitive advantage in a high-barriers market (cardiac, extracorporeal, implants). This IP-driven niche supports durable customer relationships and licensing or device integration opportunities.

Bears Say

Sharp Revenue ContractionSignificant and sustained top-line deterioration undermines economies of scale and suggests weak commercial traction or customer concentration. Over months this reduces bargaining power with partners, limits ability to absorb fixed costs, and makes margin recovery harder absent clear commercial turnaround.

Persistent Negative Free Cash FlowConsistent negative free cash flow indicates ongoing cash burn from operations and investments. This erodes liquidity over time, forces reliance on external funding or equity raises, and constrains the company's ability to invest in sales, regulatory processes, or scale manufacturing without diluting shareholders.

Deteriorating Profitability / Negative ROETransition from prior profitability to growing losses and negative returns on equity signals weak operating leverage and cost pressures. If losses persist, the equity cushion will erode, reducing strategic flexibility and increasing likelihood of financing events that could alter ownership or strategy.

CLBIO FAQ

What was Corline Biomedical AB’s price range in the past 12 months?

Corline Biomedical AB lowest stock price was kr7.90 and its highest was kr27.20 in the past 12 months.

What is Corline Biomedical AB’s market cap?

Corline Biomedical AB’s market cap is kr391.89M.

When is Corline Biomedical AB’s upcoming earnings report date?

Corline Biomedical AB’s upcoming earnings report date is May 08, 2026 which is in 75 days.

How were Corline Biomedical AB’s earnings last quarter?

Corline Biomedical AB released its earnings results on Feb 17, 2026. The company reported -kr0.197 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.197.

Is Corline Biomedical AB overvalued?

According to Wall Street analysts Corline Biomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Corline Biomedical AB pay dividends?

Corline Biomedical AB does not currently pay dividends.

What is Corline Biomedical AB’s EPS estimate?

Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Corline Biomedical AB have?

Corline Biomedical AB has 25,613,550 shares outstanding.

What happened to Corline Biomedical AB’s price movement after its last earnings report?

Corline Biomedical AB reported an EPS of -kr0.197 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.864%.

Which hedge fund is a major shareholder of Corline Biomedical AB?

Currently, no hedge funds are holding shares in SE:CLBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.